Organigram Shareholders Approve Sanity Group Acquisition and Key Resolutions at 2026 Annual Meeting
Organigram Global has announced that its shareholders have overwhelmingly approved the company’s previously disclosed acquisition of Sanity Group GmbH, along with several other important resolutions, during its annual general and special meeting held on March 30, 2026. The strong shareholder support marks a significant milestone for Organigram as it continues to expand its global footprint and strengthen its position in the cannabis industry.
At the meeting, shareholders voted decisively in favor of the resolution required to complete the acquisition of Sanity Group, a European cannabis company, as well as a related private placement financing involving BT DE Investments Inc., a wholly owned subsidiary of British American Tobacco. The approval represents a key step forward in finalizing the transaction, which is expected to close in April 2026, subject to customary conditions.
The resolution authorizing the transaction received approval from 93% of the votes cast at the meeting, excluding votes associated with shares owned or controlled by British American Tobacco and its affiliates, in accordance with applicable regulatory requirements. This high level of support underscores investor confidence in Organigram’s strategic direction and the anticipated benefits of the acquisition.
Under the terms of the approved transaction, Organigram will indirectly acquire all remaining outstanding shares of Sanity Group that it does not already own. Additionally, the company will issue up to 96.3 million common shares to Sanity Group shareholders and to British American Tobacco as part of the acquisition and the private placement financing.
The acquisition is expected to be financially accretive, contributing positively to Organigram’s revenue and profitability. Sanity Group reported positive EBITDA in 2025, making it a valuable addition to Organigram’s portfolio. By integrating Sanity Group’s operations, Organigram aims to achieve greater scale and enhance its overall financial performance.
Strategically, the transaction is set to strengthen Organigram’s leadership in the global cannabis market. The company currently holds the top position in Canada’s adult-use recreational cannabis market. Upon completion of the acquisition, Organigram will also establish a strong presence in Germany’s rapidly expanding medical cannabis sector, which is recognized as the second-largest federally legal cannabis market in the world after Canada.
A key advantage of the acquisition lies in the establishment of a vertically integrated European hub. Sanity Group brings with it an experienced local leadership team, an extensive network of strategic partners across the cannabis value chain, and deep expertise in commercial, operational, medical, and regulatory areas. This infrastructure is expected to accelerate Organigram’s expansion into European markets and support long-term growth initiatives.
Sanity Group has also demonstrated innovation in the European cannabis space. It operates the first two legal cannabis specialty retail stores in Europe as part of scientific pilot programs in Switzerland. These pilot projects provide valuable operational insights and enhance credibility for participation in future cannabis initiatives, including potential pilot programs in Germany and other European jurisdictions.
The combination of Organigram’s established brands and intellectual property with Sanity Group’s European capabilities is expected to unlock new opportunities for product development and market expansion. Supported by the Product Development Collaboration (PDC), the integrated company aims to deliver next-generation cannabis products tailored to the needs of European medical markets, backed by scientific research and innovation.
While shareholder approval represents a major milestone, the transaction remains subject to several closing conditions. These include the successful completion of the private placement financing and the arrangement of senior secured credit facilities with ATB Financial. Organigram has already obtained foreign direct investment clearance for the transaction, further advancing the process toward completion.
In addition to approving the acquisition, shareholders also voted in favor of all other matters presented at the meeting.
One of the key agenda items was the election of directors. All ten nominees listed in the company’s management information circular were successfully elected to the board. Each nominee received strong support from shareholders, with approval rates exceeding 98% in most cases. The elected directors include Peter Amirault, James Yamanaka, Dexter John, Stephen Smith, Geoffrey Machum, Sherry Porter, Marni Wieshofer, Simon Ashton, Karina Gehring, and Craig Harris. Their continued leadership is expected to provide stability and strategic guidance as the company executes its growth plans.
Following the meeting, the board of directors reviewed and confirmed the composition of its committees, which remain unchanged. The Investment Committee continues to be chaired by Dexter John and includes Stephen Smith, Marni Wieshofer, Simon Ashton, and Craig Harris. The Governance, Nominating and Sustainability Committee is chaired by Geoffrey Machum, with members Sherry Porter, Dexter John, and Craig Harris. The Audit Committee is led by Stephen Smith and includes Dexter John, Marni Wieshofer, and Simon Ashton, while the Compensation Committee is chaired by Sherry Porter and includes Geoffrey Machum and Karina Gehring.
Shareholders also approved the appointment of PricewaterhouseCoopers LLP as the company’s auditor for the coming year. The appointment received 97% support from votes cast at the meeting, and the board has been authorized to determine the auditor’s remuneration.
Another important resolution approved at the meeting relates to Organigram’s Long-Term Omnibus Equity Incentive Plan. Shareholders voted in favor of authorizing all unallocated awards under the plan, including stock options, restricted share units, performance share units, and deferred share units. This resolution received 94% approval, reflecting shareholder support for the company’s approach to incentivizing and retaining key talent.
Overall, the outcomes of the annual general and special meeting highlight strong shareholder alignment with Organigram’s strategic vision and growth initiatives. The approval of the Sanity Group acquisition, in particular, represents a transformative step for the company as it expands beyond North America into key European markets.
With the anticipated closing of the transaction in April 2026, Organigram is poised to enhance its global presence, diversify its revenue streams, and capitalize on emerging opportunities in the international cannabis industry. The integration of Sanity Group is expected to provide a solid foundation for long-term growth, innovation, and value creation for shareholders.
About Organigram Global Inc.
Organigram Global Inc. is a NASDAQ Global Select Market and TSX listed company whose wholly owned subsidiary, Organigram Inc., is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. Through its acquisition of Collective Project Limited, Organigram Global participates in the U.S. and Canadian cannabinoid beverage markets. Organigram is focused on producing high-quality cannabis for adult consumers, as well as developing international business partnerships to extend the Company’s global footprint. Organigram has also developed and acquired a portfolio of cannabis brands, including Edison, Big Bag O’ Buds, SHRED, SHRED’ems, Monjour, Tremblant Cannabis, Collective Project, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac Supérieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba. The Company also operates two additional cannabis processing facilities in Southwestern Ontario; one in Aylmer and the other in London. The facility in Aylmer houses best-in-class CO2 and Hydrocarbon extraction capabilities, and is optimized for formulation refinement, post-processing of minor cannabinoids, and pre-roll production. The facility in London will be optimized for labelling, packaging, and national fulfillment. The Company is regulated by Health Canada under the Cannabis Act and the Cannabis Regulations (Canada).
